Rare Case: Woman’s Cancer Goes into Remission Without Treatment

A remarkable case involves a woman whose cancerous tumor on her arm is now in remission, attributed to a biopsy that triggered a powerful immune response. This unique scenario exemplifies how a biopsy can potentially change the fate of some cancer patients.

She is one of only nine known cases where a biopsy uncovered this specific type of cancer affecting connective tissue, which spontaneously resolved within weeks.

“It’s quite extraordinary,” says Toby Lawrence from the Marseille Lumigny Immunology Center, not directly involved in this case. “This suggests there was an immune activation in response to the biopsy injury, rapidly halting tumor growth.”

The 59-year-old woman noticed a rapidly enlarging lump, which reached two centimeters, before seeking medical attention. “The symptoms were escalating quickly and causing discomfort. She was understandably concerned,” states Rohit Sharma from Marshfield Clinic Health System in Wisconsin.

Sharma and his team marked the tumor’s location with tattoo ink and performed a thin-needle biopsy. They identified the growth as a myxofibrosarcoma, which contained highly malignant cells, posing a risk of metastasis. “Cancer often leads to fatal metastasis,” Sharma warns.

Two weeks later, the woman returned for tumor removal surgery, but astonishingly, the tumor had completely vanished. “She reported symptom relief within just three to four days post-biopsy,” says Sharma.

To confirm the disappearance of the tumor, the surgical team removed surrounding tissue, which showed no cancer cells. “The timing indicates that an immune response was activated,” Sharma explains. The phenomenon of cancer disappearing post-biopsy is extremely rare, typically observed in cancers that the immune system can easily identify, such as skin cancers.

A biopsy can destroy some cancer cells and release inflammatory signals that activate immune cells, like natural killer cells, which can eliminate damaged tumor tissue within days. This could trigger an even stronger immune response as T cells identify and attack remaining cancerous cells.

However, such an extraordinary immune reaction does not occur for most individuals. Factors like genetics and environmental triggers likely play a role in this rare phenomenon, according to Lawrence.

By analyzing the genomes and medical histories of these exceptional cases, researchers aim to uncover strategies that could enhance overall cancer treatment efficacy. Understanding the unique immune responses in mice with cancer resulting from minor tissue damage may hold the key to unraveling these mechanisms, suggests Caetano Reis e Souza at the Francis Crick Institute in London. “If we can learn how biopsies expose cancer cells to the immune system, it might pave the way for novel therapeutic drugs,” he posits.

Sharma’s research team is planning to explore this phenomenon further in the upcoming years by establishing a database of similar unique cancer cases.